126 related articles for article (PubMed ID: 33836461)
1. Serum lipid profiling analysis and potential marker discovery for ovarian cancer based on liquid chromatography-Mass spectrometry.
Wang Y; Wang Y; Chen C; Ren F; Cao R; Wang Y; Han P; Zhang X; Xu C; Liu X; Xu G
J Pharm Biomed Anal; 2021 May; 199():114048. PubMed ID: 33836461
[TBL] [Abstract][Full Text] [Related]
2. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry.
Zhang T; Wu X; Yin M; Fan L; Zhang H; Zhao F; Zhang W; Ke C; Zhang G; Hou Y; Zhou X; Lou G; Li K
Clin Chim Acta; 2012 May; 413(9-10):861-8. PubMed ID: 22309680
[TBL] [Abstract][Full Text] [Related]
3. Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry.
Li J; Xie H; Li A; Cheng J; Yang K; Wang J; Wang W; Zhang F; Li Z; Dhillon HS; Openkova MS; Zhou X; Li K; Hou Y
Oncotarget; 2017 Jul; 8(29):46834-46845. PubMed ID: 27564116
[TBL] [Abstract][Full Text] [Related]
4. Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based nontargeted and targeted analyses.
Lu X; Li Y; Xia B; Bai Y; Zhang K; Zhang X; Xie H; Sun F; Hou Y; Li K
Int J Cancer; 2019 Apr; 144(8):2033-2042. PubMed ID: 30114318
[TBL] [Abstract][Full Text] [Related]
5. Large-scale profiling of metabolic dysregulation in ovarian cancer.
Ke C; Hou Y; Zhang H; Fan L; Ge T; Guo B; Zhang F; Yang K; Wang J; Lou G; Li K
Int J Cancer; 2015 Feb; 136(3):516-26. PubMed ID: 24895217
[TBL] [Abstract][Full Text] [Related]
6. A serum lipidomic strategy revealed potential lipid biomarkers for early-stage cervical cancer.
Cheng F; Wen Z; Feng X; Wang X; Chen Y
Life Sci; 2020 Nov; 260():118489. PubMed ID: 32976882
[TBL] [Abstract][Full Text] [Related]
7. Plasma lipidomics reveals potential lipid markers of major depressive disorder.
Liu X; Li J; Zheng P; Zhao X; Zhou C; Hu C; Hou X; Wang H; Xie P; Xu G
Anal Bioanal Chem; 2016 Sep; 408(23):6497-507. PubMed ID: 27457104
[TBL] [Abstract][Full Text] [Related]
8. Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer.
Chen J; Zhang X; Cao R; Lu X; Zhao S; Fekete A; Huang Q; Schmitt-Kopplin P; Wang Y; Xu Z; Wan X; Wu X; Zhao N; Xu C; Xu G
J Proteome Res; 2011 May; 10(5):2625-32. PubMed ID: 21456628
[TBL] [Abstract][Full Text] [Related]
9. SPME-LC/MS-based serum metabolomic phenotyping for distinguishing ovarian cancer histologic subtypes: a pilot study.
Olkowicz M; Rosales-Solano H; Kulasingam V; Pawliszyn J
Sci Rep; 2021 Nov; 11(1):22428. PubMed ID: 34789766
[TBL] [Abstract][Full Text] [Related]
10. Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS).
Li J; Wang Z; Liu W; Tan L; Yu Y; Liu D; Wei Z; Zhang S
Cancer Biomark; 2023; 37(2):67-84. PubMed ID: 37248885
[TBL] [Abstract][Full Text] [Related]
11. Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.
Xie H; Hou Y; Cheng J; Openkova MS; Xia B; Wang W; Li A; Yang K; Li J; Xu H; Yang C; Ma L; Li Z; Fan X; Li K; Lou G
Oncotarget; 2017 May; 8(19):32134-32146. PubMed ID: 28389631
[TBL] [Abstract][Full Text] [Related]
12. [Discrimination and clinical value of plasma metabolomic profiles in multidrug resistant epithelial ovarian cancer].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):896-902. PubMed ID: 29262505
[No Abstract] [Full Text] [Related]
13. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling.
Zhang T; Wu X; Ke C; Yin M; Li Z; Fan L; Zhang W; Zhang H; Zhao F; Zhou X; Lou G; Li K
J Proteome Res; 2013 Jan; 12(1):505-12. PubMed ID: 23163809
[TBL] [Abstract][Full Text] [Related]
15. Development of lipidomic platform and phosphatidylcholine retention time index for lipid profiling of rosuvastatin treated human plasma.
Choi JM; Kim TE; Cho JY; Lee HJ; Jung BH
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():157-65. PubMed ID: 24316528
[TBL] [Abstract][Full Text] [Related]
16. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
[TBL] [Abstract][Full Text] [Related]
17. Quantitative assessment of serum heat shock protein 27 for the diagnosis of epithelial ovarian cancer using targeted proteomics coupled with immunoaffinity enrichment.
Yang T; Xu P; Gu L; Xu Z; Ge W; Li Q; Xu F
Clin Chim Acta; 2019 Feb; 489():96-102. PubMed ID: 30502327
[TBL] [Abstract][Full Text] [Related]
18. [Nontargeted lipidomic analysis of sera from sepsis patients based on ultra-high performance liquid chromatography-mass spectrometry/mass spectrometry].
Wang S; Liang J; Shi H; Xia Y; Li J; Wu W; Wang H; Wu W
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2022 Apr; 34(4):346-351. PubMed ID: 35692196
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis.
Zhang W; Peng P; Ou X; Shen K; Wu X
BMC Cancer; 2019 Nov; 19(1):1095. PubMed ID: 31718609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
